M
Martín Prieto
Researcher at Carlos III Health Institute
Publications - 184
Citations - 9548
Martín Prieto is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 45, co-authored 175 publications receiving 8981 citations. Previous affiliations of Martín Prieto include University of Barcelona & University of Valencia.
Papers
More filters
Journal ArticleDOI
HCV-related fibrosis progression following liver transplantation: increase in recent years
Marina Berenguer,Linda D. Ferrell,Jessica J. Watson,Martín Prieto,Michael Kim,Miguel Rayón,Juan Córdoba,Antonio Herola,Nancy L. Ascher,José Mir,Joaquín Berenguer,Teresa L. Wright +11 more
TL;DR: HCV-related disease progression is accelerated in immunocompromised compared to immunOCompetent patients, with a progressive increase in patients who have recently undergone liver transplantation.
Journal ArticleDOI
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
Marina Berenguer,Martín Prieto,Fernando San Juan,José M. Rayón,Fernando Martinez,Domingo Carrasco,Ángel Moya,Francisco Orbis,José Mir,Joaquín Berenguer +9 more
TL;DR: In this paper, the authors describe the natural history of HCV-infected recipients, particularly to determine whether survival has decreased in recent years, and compare this outcome with that observed in non-HCVinfected cirrhosis controls.
Journal ArticleDOI
Natural History of Clinically Compensated Hepatitis C Virus–Related Graft Cirrhosis After Liver Transplantation
Marina Berenguer,Martín Prieto,José M. Rayón,J. Mora,M. Pastor,Vicente Ortiz,Domingo Carrasco,Fernando San Juan,Manuel‐de‐Juan Burgueño,José Mir,Joaquín Berenguer +10 more
TL;DR: The natural history of clinically compensated HCV‐graft cirrhosis is shortened when compared with immunocompetent patients, and if retransplantation is considered, it should be performed promptly once decompensation develops.
Journal ArticleDOI
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
Martín Prieto,Marina Berenguer,José M. Rayón,Juan Córdoba,Lidia Argüello,Domingo Carrasco,Antonio García-Herola,Vicente Olaso,Manuel de Juan,Gobernado M,José Mir,Joaquín Berenguer +11 more
TL;DR: HCV genotype 1b–infected liver recipients are at a high risk of developing graft cirrhosis in the first 4 to 5 years following transplantation, especially those with previous rejection episodes.
Journal ArticleDOI
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns,Didier Samuel,Edward Gane,David Mutimer,Geoff McCaughan,Maria Buti,Martín Prieto,Jose Luis Calleja,Markus Peck-Radosavljevic,Beat Müllhaupt,Kosh Agarwal,Peter W Angus,Eric M. Yoshida,Massimo Colombo,Mario Rizzetto,Hadas Dvory-Sobol,Jill Denning,Sarah Arterburn,Phillip S. Pang,Diana M. Brainard,John G. McHutchison,Jean-François Dufour,Hans Van Vlierberghe,Bart van Hoek,Xavier Forns +24 more
TL;DR: An open-label study assessing the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease found high rates of sustained virological response 12 weeks after treatment.